Captor Therapeutics S.A.
Develops Targeted Protein Degradation therapies for cancer and autoimmune diseases.
CTX | WAR
Overview
Corporate Details
- ISIN(s):
- PLCPTRT00014 (+1 more)
- LEI:
- 259400JHH1S2I2S4O735
- Country:
- Poland
- Address:
- Wrocław Duńska 11, 54-427 Wrocław
Description
Captor Therapeutics is a biopharmaceutical company focused on the discovery and development of novel therapeutics for diseases with high unmet medical needs. The company specializes in Targeted Protein Degradation (TPD), a technology that enables the elimination of disease-causing proteins previously considered "undruggable." Its core research and development activities are centered on creating new treatments for cancer and autoimmune diseases. To achieve this, Captor Therapeutics utilizes its proprietary Optigrade™ platform. This integrated drug discovery engine combines advanced technologies, including structural biology, proteomics, molecular modeling, and protein engineering, to identify and optimize novel drug candidates. The platform is designed to accelerate the development of degraders with superior therapeutic properties, aiming to provide new treatment options for severe conditions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2022-12-28 14:41 |
Załącznik do raportu
|
Polish | 359.2 KB | ||
| 2022-12-28 14:41 |
Informacja o transakcji na akcjach Spółki uzyskana w trybie art. 19 MAR - Conte…
|
Polish | 512 bytes | ||
| 2022-12-21 14:06 |
Zawarcie aneksu do umowy o współpracy badawczej z Sosei Heptares - Content (PL)
|
Polish | 1.1 KB | ||
| 2022-12-09 17:39 |
Załącznik do raportu
|
Polish | 182.2 KB | ||
| 2022-12-09 17:39 |
Informacja o wygaśnięciu zastawu na akcjach Spółki uzyskana w trybie art. 19 MA…
|
Polish | 545 bytes | ||
| 2022-12-02 19:18 |
Załącznik do raportu
|
Polish | 183.8 KB | ||
| 2022-12-02 19:18 |
Informacja o transakcji na akcjach Spółki uzyskana w trybie art. 19 MAR - Conte…
|
Polish | 644 bytes | ||
| 2022-11-24 17:15 |
Rozszerzony skonsolidowany raport kwartalny za III kwartał 2022 roku
|
Polish | 1.8 MB | ||
| 2022-11-23 15:39 |
Dopuszczenie i wprowadzenie do obrotu giełdowego akcji zwykłych na okaziciela s…
|
Polish | 1005 bytes | ||
| 2022-11-22 14:06 |
Komunikat Krajowego Depozytu Papierów Wartościowych S.A. w sprawie warunkowej r…
|
Polish | 1.2 KB | ||
| 2022-11-16 17:39 |
Ostateczne rozliczenie wyników Audytu z NCBiR - Content (PL)
|
Polish | 2.2 KB | ||
| 2022-11-14 07:46 |
Zawarcie umowy o współpracy z Ono Pharmaceutical Co., Ltd. i ujawnienie opóźnio…
|
Polish | 4.8 KB | ||
| 2022-11-07 15:25 |
Zakończenie subskrypcji akcji serii L emitowanej w związku z realizacją program…
|
Polish | 4.1 KB | ||
| 2022-10-31 17:27 |
Informacja o statusie projektu CT-04 - Content (PL)
|
Polish | 2.9 KB | ||
| 2022-09-28 15:03 |
Załącznik do raportu
|
Polish | 411.2 KB |
Automate Your Workflow. Get a real-time feed of all Captor Therapeutics S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Captor Therapeutics S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Captor Therapeutics S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
